Inclusion:
1. Newly diagnosed untreated classic Hodgkin lymphoma
2. Age 60 years or over
3. Advanced stage defined as: stage IIB with bulk or E-lesions, stage III or stage IV based on PET-CT assessment. Bulk is defined as any lesion ≥ 10cm or a mediastinal mass ≥ 1/3 of the thoracic diameter measured at T5/T6
4. In the view of the investigator, fit for combination chemotherapy (includes those who would require planned dose reduction although no lower than 50% doxorubicin)
5. Written informed consent
6. Measurable disease on contrast-enhanced CT as defined by Cheson et al., 2014 (Nodal lesion of longest diameter 1.5 cm or extranodal lesion of longest diameter 1.0 cm)
7. FDG avid disease on baseline 18 FDG-PET-CT scan
8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
9. Adequate bone marrow function (Platelets ≥ 75 x 109/L without platelet transfusion for 72 hours, Neutrophils ≥ 1.0 x 109/L without G-CSF for 7 days)
10. Adequate liver function tests (ALT / AST ≤ 2.5 x ULN, total serum bilirubin ≤1.5 x ULN)
11. Creatinine Clearance ≥ 30 ml/min as defined by the Cockroft-Gault equation
12. Adequate cardiac function as determined by a transthoracic echocardiogram or multiplanar gated radionuclide cardiac angiography (MUGA) demonstrating left ventricular ejection fraction is ≥ 50% and confirming the absence of severe valvular heart disease
13. Willing to comply with the contraceptive requirements of the trial
14. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures